Session Information
Date: Tuesday, September 24, 2019
Session Title: Drug-Induced Movement Disorders
Session Time: 1:45pm-3:15pm
Location: Agora 2 West, Level 2
Objective: To characterize gait performance recorded from psychiatric patients on neuroleptics (PPN) and to compare it to Parkinson’s disease (PD) patients and healthy controls (HC).
Background: Neuroleptic-induced parkinsonism is a syndrome which is closely related to PD presenting a continuum of parkinsonian signs of diverse severity. PPN should be monitored for worsening of symptoms and transition to overt parkinsonism. Quantitative monitoring of gait may serve such a purpose.
Method: Consecutive hospitalized PPN were recruited, examine and rated according to the part III (motor examination) of the MDS-UPDRS to assess presence of parkinsonian signs. All subjects performed a 10-meter ‘timed up and go’ test while a smartphone-based motion capture system is attached to their sternum. Gait parameters and motor UPDRS scores were compared to those obtained from consecutive idiopathic PD patients attending a movement disorders clinic and healthy controls (HC).
Results: Thirty-two PPN (19 males, age 43.1 ± 11.3 years), 11 PD patients (7 males, Age 50.6 ± 7.0 years, disease duration 7.5 ± 2.8 years) and 18 HC (7 males, age 46.7 ± 8.9 years) were enrolled to the study. Evidently, the motor UPDRS was higher in the PD group than in the PPN (28.4 ± 5.9 vs. 17.2 ± 9.0 years, respectively; p=0.007). PPN showed significantly longer total TUG time (p=0.001), walking straight forward (p=0.002) and rotation (p<0.001) times than the HC but shorter times than PD (p=0.03, p=0.03 and p<0.001 respectively). PPN showed significantly longer sitting-down time (p=0.001), lower step count (p=0.002) and a longer step length (p<0.001) than HC and higher step-to-step correlation (p=0.04) than PD. In the PPN group, females walked straight-forward significantly slower (p=0.006), had a longer total TUG time (p=0.006), had a lower step-to-step correlation in AP direction (p=0.03), a shorter step length (p<0.001) and a higher step count (p=0.001) than males. There were no gender-related differences in gait parameters in the PD group.
Conclusion: Gait performance of PPN is significantly worse than HC but is better than PD patients in most parameters. Females showed lower performance in PPN.
To cite this abstract in AMA style:
S. Hassin-Baer, T. Fay-Karmon, V. Livneh, S. Israeli-Korn, Y. Rubel, K. Tchelet, Z. Yekutieli, M. Linder, H. Yahalom, G. Yahalom. Smartphone-based gait assessment of psychiatric patients on neuroleptics [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/smartphone-based-gait-assessment-of-psychiatric-patients-on-neuroleptics/. Accessed November 21, 2024.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/smartphone-based-gait-assessment-of-psychiatric-patients-on-neuroleptics/